A randomized controlled study to examine the effects of a triple therapy with vonoprazan or rabeprazole against standard triple therapy-failed patients.

A randomized controlled study to examine the effects of a triple therapy with vonoprazan or rabeprazole against standard triple therapy-failed patients. - A triple therapy with vonoprazan or rabeprazole against standard triple therapy-failed patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016601

Enrollment

Registered

2015-02-26

Start date

2015-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

vonoprazan, metronidazole, amoxicillin rabeprazole, metronidazole, amoxicillin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who failed standard triple therapy

Exclusion criteria

Exclusion criteria: 1. Patients who cannot cancel a proton pump inhibitor for 2 weeks before judgment after re-eradication therapy. 2. Patients who have past history of drug allergy. 3. Patients who have severe diseases affecting the kidney, the heart, and the liver. 4. Patients who are pregnant, who may be pregnant, or who are nursing.

Design outcomes

Primary

Measure	Time frame
Comparison on an eradication rate between a triple therapy with vonoprazan and a triple therapy with rabeprazole	—

Secondary

Measure	Time frame
Comparison of adverse effects between a triple therapy with vonoprazan and a triple therapy with rabeprazole	—

Countries

Japan

Contacts

Public ContactMariko Hojo

Juntendo University School of Medicine Department of Gastroenterology

mhojo@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026